Epidemiology and Clinical Outcomes of Patients with Carbapenem- Resistant Klebsiella pneumoniae Bacteriuria

Zubair A. Qureshi, Alveena Syed, Lloyd G. Clarke, Yohei Doi, Ryan K. Shields

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria is a frequently encountered clinical condition, but its clinical impact is unknown. We conducted a retrospective cohort study to define the epidemiology and outcomes for patients with CRKP bacteriuria. Patients with positive urine cultures for CRKP were classified as having asymptomatic bacteriuria (ASB) or symptomatic urinary tract infection (UTI). Among 105 patients with CRKP bacteriuria, 80% (84/105 patients) and 20% (21/105 patients) had ASB and UTI, respectively. Older age (P=0.002) and higher Charlson's comorbidity index scores (P=0.001) were associated with ASB. The median duration of hospitalization prior to CRKP bacteriuria was significantly longer for patients with ASB versus UTI (8.5 versus 2 days; P=0.05). In multivariate analysis, male sex (odds ratio [OR], 4.69 [95% confidence interval (CI), 1.44 to 15.26]; P=0.01), solid-organ transplantation (OR, 4.50 [95% CI, 1.39 to 14.52]; P= 0.01), and neurogenic bladder (OR, 18.62 [95% CI, 1.75 to 197.52]; P=0.01) were independently associated with UTI. Ten percent (8/84) of the patients with ASB received antimicrobial therapy. The treatment success rate for patients with UTIs was 90% (19/21 patients), including all patients who received doxycycline (n=9). The overall 30-day mortality rate was 6% (6/105 patients); the deaths were unrelated to CRKP infections. Secondary CRKP infections, including UTIs, were notably absent among patients with ASB who were followed for 90 days. In conclusion, identification of CRKP in the urine was most commonly associated with ASB and did not lead to subsequent infections or death among asymptomatic patients. Factors associated with UTIs included male sex, solid-organ transplantation, and neurogenic bladder. Doxycycline may be an effective therapy for CRKP UTIs.

Original languageEnglish
Pages (from-to)3100-3104
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Bacteriuria
Carbapenems
Klebsiella pneumoniae
Epidemiology
Urinary Tract Infections
Klebsiella Infections
Neurogenic Urinary Bladder
Doxycycline
Odds Ratio
Organ Transplantation
Confidence Intervals
Urine
Sex Ratio
Comorbidity
Hospitalization

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Qureshi, Zubair A. ; Syed, Alveena ; Clarke, Lloyd G. ; Doi, Yohei ; Shields, Ryan K. / Epidemiology and Clinical Outcomes of Patients with Carbapenem- Resistant Klebsiella pneumoniae Bacteriuria. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 6. pp. 3100-3104.
@article{aab02f9f795f499b88d975232a8b346b,
title = "Epidemiology and Clinical Outcomes of Patients with Carbapenem- Resistant Klebsiella pneumoniae Bacteriuria",
abstract = "Carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria is a frequently encountered clinical condition, but its clinical impact is unknown. We conducted a retrospective cohort study to define the epidemiology and outcomes for patients with CRKP bacteriuria. Patients with positive urine cultures for CRKP were classified as having asymptomatic bacteriuria (ASB) or symptomatic urinary tract infection (UTI). Among 105 patients with CRKP bacteriuria, 80{\%} (84/105 patients) and 20{\%} (21/105 patients) had ASB and UTI, respectively. Older age (P=0.002) and higher Charlson's comorbidity index scores (P=0.001) were associated with ASB. The median duration of hospitalization prior to CRKP bacteriuria was significantly longer for patients with ASB versus UTI (8.5 versus 2 days; P=0.05). In multivariate analysis, male sex (odds ratio [OR], 4.69 [95{\%} confidence interval (CI), 1.44 to 15.26]; P=0.01), solid-organ transplantation (OR, 4.50 [95{\%} CI, 1.39 to 14.52]; P= 0.01), and neurogenic bladder (OR, 18.62 [95{\%} CI, 1.75 to 197.52]; P=0.01) were independently associated with UTI. Ten percent (8/84) of the patients with ASB received antimicrobial therapy. The treatment success rate for patients with UTIs was 90{\%} (19/21 patients), including all patients who received doxycycline (n=9). The overall 30-day mortality rate was 6{\%} (6/105 patients); the deaths were unrelated to CRKP infections. Secondary CRKP infections, including UTIs, were notably absent among patients with ASB who were followed for 90 days. In conclusion, identification of CRKP in the urine was most commonly associated with ASB and did not lead to subsequent infections or death among asymptomatic patients. Factors associated with UTIs included male sex, solid-organ transplantation, and neurogenic bladder. Doxycycline may be an effective therapy for CRKP UTIs.",
author = "Qureshi, {Zubair A.} and Alveena Syed and Clarke, {Lloyd G.} and Yohei Doi and Shields, {Ryan K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/AAC.02445-13",
language = "English",
volume = "58",
pages = "3100--3104",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

Epidemiology and Clinical Outcomes of Patients with Carbapenem- Resistant Klebsiella pneumoniae Bacteriuria. / Qureshi, Zubair A.; Syed, Alveena; Clarke, Lloyd G.; Doi, Yohei; Shields, Ryan K.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 6, 01.01.2014, p. 3100-3104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epidemiology and Clinical Outcomes of Patients with Carbapenem- Resistant Klebsiella pneumoniae Bacteriuria

AU - Qureshi, Zubair A.

AU - Syed, Alveena

AU - Clarke, Lloyd G.

AU - Doi, Yohei

AU - Shields, Ryan K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria is a frequently encountered clinical condition, but its clinical impact is unknown. We conducted a retrospective cohort study to define the epidemiology and outcomes for patients with CRKP bacteriuria. Patients with positive urine cultures for CRKP were classified as having asymptomatic bacteriuria (ASB) or symptomatic urinary tract infection (UTI). Among 105 patients with CRKP bacteriuria, 80% (84/105 patients) and 20% (21/105 patients) had ASB and UTI, respectively. Older age (P=0.002) and higher Charlson's comorbidity index scores (P=0.001) were associated with ASB. The median duration of hospitalization prior to CRKP bacteriuria was significantly longer for patients with ASB versus UTI (8.5 versus 2 days; P=0.05). In multivariate analysis, male sex (odds ratio [OR], 4.69 [95% confidence interval (CI), 1.44 to 15.26]; P=0.01), solid-organ transplantation (OR, 4.50 [95% CI, 1.39 to 14.52]; P= 0.01), and neurogenic bladder (OR, 18.62 [95% CI, 1.75 to 197.52]; P=0.01) were independently associated with UTI. Ten percent (8/84) of the patients with ASB received antimicrobial therapy. The treatment success rate for patients with UTIs was 90% (19/21 patients), including all patients who received doxycycline (n=9). The overall 30-day mortality rate was 6% (6/105 patients); the deaths were unrelated to CRKP infections. Secondary CRKP infections, including UTIs, were notably absent among patients with ASB who were followed for 90 days. In conclusion, identification of CRKP in the urine was most commonly associated with ASB and did not lead to subsequent infections or death among asymptomatic patients. Factors associated with UTIs included male sex, solid-organ transplantation, and neurogenic bladder. Doxycycline may be an effective therapy for CRKP UTIs.

AB - Carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria is a frequently encountered clinical condition, but its clinical impact is unknown. We conducted a retrospective cohort study to define the epidemiology and outcomes for patients with CRKP bacteriuria. Patients with positive urine cultures for CRKP were classified as having asymptomatic bacteriuria (ASB) or symptomatic urinary tract infection (UTI). Among 105 patients with CRKP bacteriuria, 80% (84/105 patients) and 20% (21/105 patients) had ASB and UTI, respectively. Older age (P=0.002) and higher Charlson's comorbidity index scores (P=0.001) were associated with ASB. The median duration of hospitalization prior to CRKP bacteriuria was significantly longer for patients with ASB versus UTI (8.5 versus 2 days; P=0.05). In multivariate analysis, male sex (odds ratio [OR], 4.69 [95% confidence interval (CI), 1.44 to 15.26]; P=0.01), solid-organ transplantation (OR, 4.50 [95% CI, 1.39 to 14.52]; P= 0.01), and neurogenic bladder (OR, 18.62 [95% CI, 1.75 to 197.52]; P=0.01) were independently associated with UTI. Ten percent (8/84) of the patients with ASB received antimicrobial therapy. The treatment success rate for patients with UTIs was 90% (19/21 patients), including all patients who received doxycycline (n=9). The overall 30-day mortality rate was 6% (6/105 patients); the deaths were unrelated to CRKP infections. Secondary CRKP infections, including UTIs, were notably absent among patients with ASB who were followed for 90 days. In conclusion, identification of CRKP in the urine was most commonly associated with ASB and did not lead to subsequent infections or death among asymptomatic patients. Factors associated with UTIs included male sex, solid-organ transplantation, and neurogenic bladder. Doxycycline may be an effective therapy for CRKP UTIs.

UR - http://www.scopus.com/inward/record.url?scp=84901254999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901254999&partnerID=8YFLogxK

U2 - 10.1128/AAC.02445-13

DO - 10.1128/AAC.02445-13

M3 - Article

C2 - 24637691

AN - SCOPUS:84901254999

VL - 58

SP - 3100

EP - 3104

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -